Determination of a new antibacterial agent (AT-2266) and its metabolites in plasma and urine by high-performance liquid chromatography.
A high-performance liquid chromatographic method has been developed which enables accurate determination of a new synthetic antibacterial agent, AT-2266, and its metabolite, M-2, in plasma, and AT-2266 and its five metabolites, M-1, M-2, M-3, M-4 and M-5, in urine. AT-2266 is extracted as ethyl carbamate with chloroform containing 1% ethyl chloroformate and assayed on a liquid chromatograph equipped with an ultraviolet detector at 340 nm. Accurate determinations are possible over a concentration range of 0.1-10 micrograms/ml AT-2266 in plasma, and 1-500 micrograms/ml AT-2266 in urine. The coefficient of variation at the 2 micrograms/ml level of AT-2266 is 1.9% (n = 6). The minimum detectable concentrations of AT-2266 in plasma and urine are 0.01 micrograms/ml and 0.1 micrograms/ml, respectively, and those of other metabolites are similar to those of AT-2266. Plasma levels and urinary excretion of AT-2266 in a man following single oral administration (400 mg) have also been determined.
D000890:Anti-Infective Agents / Q000032:analysis* / Q000097:blood / Q000652:urine; D001711:Biotransformation; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004355:Drug Stability; D015365:Enoxacin; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D008297:Male; D009539:Nicotinic Acids / Q000032:analysis* / Q000097:blood / Q000652:urine
D000890:Anti-Infective Agents; D009539:Nicotinic Acids; D015365:Enoxacin